Why—and When—to Use a CDMO

This article is the first part of our “Best Practices in the CDMO Selection Process” series, through which we intend to provide sound advice to agile biotech companies in identifying and selecting the right Contract Development and Manufacturing Organization (CDMO) for advancing the development of their product(s), in conjunction with successfully managing a chosen CDMO to meet the company’s expectations.

Publications
Published on:
August 25, 2022

Pharmaceutical development companies of all sizes frequently outsource their Active Pharmaceutical Ingredient (API) manufacturing to CDMOs for various reasons, including: a) limited internal know-how and capacity to manufacture API according to Good Manufacturing Practice (GMP) or b) to reduce costs and timelines. In this article, we will explore three common reasons why a company might consider engaging a CDMO.

Resource optimization

Early clinical development naturally leads to a fast cycling of projects as candidate molecules are identified and prioritized. Providing staff and capital required for this fluctuation in demand is at the discretion of the company. If a company does invest capital and internal resources to expand its manufacturing capability, it’s best to keep those assets active to offset their high cost.

While cost reduction may seem like a guarantee with a CDMO, a company can truly maximize its savings with a well-planned CDMO selection strategy.
Greater technical expertise and robust infrastructure

Small virtual biotech companies and early-stage clinical companies might have limited internal capabilities and the technical expertise required to manufacture an API. Engaging a CDMO with applicable existing infrastructure and expertise can benefit the company financially while also improving overall product quality and timelines.

Cost reduction

While cost reduction may seem like a guarantee with a CDMO, a company can truly maximize its savings with a well-planned CDMO selection strategy. Initially, a company needs to ensure it’s utilizing its current internal resources to the maximum and only then identify what should be outsourced to a CDMO thus cutting unnecessary spending. More importantly, a carefully planned CDMO selection process can help to identify a CDMO offering the best overall value to the company. While such an identification, evaluation and selection process is not trivial, overall savings can be substantial if the entire process is carried out well.

If you are deciding to outsource your manufacturing or simply looking to obtain insight into the overall CDMO landscape in order to identify the right CDMO for your project, we are here to assist. Our expert team has been helping companies choose the right CDMO for more than a decade and we can be reached here.

Related news

Publications February 2, 2023
Outlook 2023: Firms Prepare For ‘World Where Health Care Has No Limits’
In the latest publication by Medtech Insights by Pharma Intelligence, executives at top device companies and other stakeholders share their expectations.
MedTech Pharma
Publications January 20, 2023
Insights on Market Access
To get her perspective on market access and what to expect in 2023, we spoke with Nerea Blanqué, Senior Vice President of Market Access and Pricing at Alira Health.
Market Access Medical Devices Pharma
Publications January 18, 2023
The State of Biopharma Funding
We spoke with Joris Pezzini, Executive Vice President of Biopharma, Alira Health, during the J.P. Morgan Healthcare Conference in San Francisco, which brings together investors and(...)
Biopharma Biotech Funding Pharma
Events January 11, 2023
MD&M West 2023
Join our colleague Carlo Stimamiglio for his presentation “MedTech CDMO: Market and M&A Trends in 2023”, as he goes over key takeaways from our upcoming 2023 US MedTech CDMO Report.
CDMO MedTech
Publications December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
Publications December 6, 2022
Review of 2021-22 and 2023 Outlook: Report on the European MedTech CDMO Industry
A return to normalcy has accelerated growth for Europe’s MedTech CDMO industry, but individual companies may be at risk given the increased competitive pressure, logistics disruption,(...)
CDMO MedTech
Publications November 10, 2022
How to Choose the Right Analytical Methods
In this article, we focus on the analytical method development around your biologics. Analytical method development is an important component of biologics development and the control(...)
Biotech CDMO Drug Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.